No Data
No Data
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
Glaukos Eyes FDA Approval for Ocular Therapy After Phase III Win
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
Stifel Nicolaus Issues a Buy Rating on Glaukos (GKOS)
Wells Fargo Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $135
Piper Sandler Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $140